Clinical Research Directory
Browse clinical research sites, groups, and studies.
Temporal Interference Stimulation Targeting Thalamus for Schizophrenia-Related Cognitive Dysfunction
Sponsor: Central South University
Summary
Prefrontal cortical dysfunction in patients with schizophrenia (SCZ) may result from impaired thalamic inputs to this region. Meanwhile, patients with SCZ exhibit a reduced GABA/glutamate ratio in the thalamus, indicating thalamic excitation/inhibition (E/I) imbalance. In addition, SCZ patients show marked reduction of sleep spindles, which are predominantly generated by the thalamic reticular nucleus. Therefore, thalamus-targeted temporal interference stimulation (TIS) may modulate the function of thalamocortical circuits, ameliorate clinical symptoms including cognitive deficits in patients with SCZ, and serve as an effective non-pharmacological intervention. This study consists of two trial components with three objectives: (1) to explore the therapeutic effect of TIS on cognitive function in patients with SCZ; (2) to explore the effect of TIS on positive symptoms in patients with SCZ; (3) to investigate the neural mechanisms underlying TIS-mediated symptom modulation in SCZ. Trial 1: This study adopts a randomized, controlled, crossover design. Participants will be randomly assigned to two groups: Group A and Group B. Clinical data from 30 patients with schizophrenia (15 participants per group) will be collected, including baseline clinical rating scale scores, cognitive assessments, electroencephalography (EEG), and magnetic resonance imaging (MRI) data. All participants will receive two sessions of TIS intervention in a crossover fashion, with a 1-week washout period between the two interventions. One day prior to each TIS session, participants will complete two training runs of the Sternberg Item-Recognition Paradigm (SIRP) to eliminate confounding learning effects. Outcome measurements including clinical scale scores, cognitive assessments, EEG and MRI data will be acquired at baseline. Task-state MRI will be recorded during both stimulation sessions. Trial 2: This trial uses a rigorous randomized controlled design. Participants will be randomized into two arms: the TIS group and the control group. Fifty patients with schizophrenia will be enrolled (25 participants per group). Baseline data will be collected, including clinical symptom ratings, cognitive function scores, EEG-derived E/I imbalance metrics, and MRI data. The intervention lasts for 2 weeks with twice-daily stimulation, totaling 20 sessions. Assessments will be performed at baseline, at the end of the 2-week intervention, and at a 4-week post-intervention follow-up to evaluate changes in clinical symptoms, cognition, EEG E/I imbalance, and brain structural and functional features. This trial aims to explore the short-term efficacy, safety, and neurobiological mechanisms of TIS for improving cognitive function in schizophrenia.
Official title: Therapeutic Efficacy and Mechanism of Temporal Interference Stimulation on Thalamic-Mediated Cognitive Impairment in Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-11
Completion Date
2027-10-31
Last Updated
2026-11-10
Healthy Volunteers
No
Interventions
temporal interference stimulation
Thalamus-targeted temporal interference stimulation delivered via Dome Medical TES NEURO-800, individualized based on individual alpha frequency with electric field optimization from T1 MRI.
Sham TIS
Sham temporal interference stimulation with identical setup; current only delivered during brief ramp-up/ramp-down periods to mimic scalp sensation without effective thalamic stimulation.
Locations (1)
Second Xiangya Hospital, Central South University
Changsha, Hunan, China